BioBeauJ launches ECM booster Celivion in Japan next year

Celivion is a collagen-based ECM product manufactured by Orthotech and sold exclusively by BioBeauJ. The company began supplying domestic hospitals and clinics in late May 2026, followed by an official launch event in September. Yang said the product's differentiation lies in a low-temperature manufacturing process that preserves important proteins and produces small, uniform particles. The company is targeting thin-skin areas like the neck and back of the hands, where the skin is thin and wrinkles are a concern.

Hospitals already carrying the product are placing repeat orders. BioBeauJ is expanding its domestic distribution network for Celivion while also pursuing the Japan expansion.

BioBeauJ is on track for its best year since founding. Consensus estimates from financial data provider FnGuide project full-year 2026 revenue of 38.1 billion won and operating profit of 10.4 billion won, representing increases of 33.6% and 146.0% from 2025. These results would surpass the previous record from 2024, when revenue reached 29.6 billion won and operating profit totaled 9.2 billion won. In the first half alone, the company earned 5.3 billion won in operating profit, already exceeding its full-year 2025 operating profit of 4.2 billion won. Yang said that "considering that earnings are concentrated in the second half, full-year results could come in slightly better than brokerage estimates."

U.S. cosmetics sales drove the first-half rebound. BioBeauJ expanded sales of its medical cosmetics brand Candolup through pharmacy chains, pop-up stores and Amazon. U.S. revenue surged from roughly 300 million won for all of 2025 to approximately 7.1 billion won in the first half of 2026 alone.

For next year, the company targets 20 billion won in Celivion revenue, with 60% coming from the domestic market and the remainder from overseas. Yang said "after cosmetics, Celivion will drive second-half earnings" and that the company is "concentrating our sales and marketing resources on raising Celivion's market share."

BioBeauJ is pursuing overseas approvals for Corena Premium, its in-house developed hyaluronic acid filler. The product received domestic approval in March 2026 and launched in September. Yang emphasized that no cross-linking agent was detected in finished-product testing, distinguishing it from competitors. He explained that fillers typically achieve viscosity and elasticity by combining hyaluronic acid with a cross-linking agent, and consumers sensitive to that ingredient may experience swelling. "Corena Premium injects smoothly, which makes it easier to shape," Yang said, outlining a strategy to target delicate procedures on the lips and neck.

European certification is under review. Approval procedures in China are proceeding through a local subsidiary. The company is preparing documents for Brazil and plans to secure approvals in all three markets next year while establishing local distribution networks.

To meet rising overseas demand, BioBeauJ plans to secure a site for a second manufacturing plant in 2027 and begin commercial production in 2029. The company is also considering expanding filler production capacity and moving cosmetics manufacturing in-house after outsourcing it previously.

Business information, not medical or legal advice. Verify regulatory status at FDA.gov.